These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11247101)

  • 1. Treatment of tardive dyskinesia with donepezil.
    Caroff SN; Campbell EC; Havey JC; Sullivan KA; Katz IR; Mann SC
    J Clin Psychiatry; 2001 Feb; 62(2):128-9. PubMed ID: 11247101
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of donepezil on tardive dyskinesia.
    Ogunmefun A; Hasnain M; Alam A; Osuala T; Regenold WT
    J Clin Psychopharmacol; 2009 Feb; 29(1):102-4. PubMed ID: 19142126
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J; Dwolatzky T; Brettholz I; Lerner V
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tardive dyskinesia with donepezil: a pilot study.
    Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
    J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil and tardive dyskinesia.
    Schopick D
    J Am Acad Child Adolesc Psychiatry; 2005 Feb; 44(2):112. PubMed ID: 15689723
    [No Abstract]   [Full Text] [Related]  

  • 6. Tardive dyskinesia with quetiapine.
    Ghelber D; Belmaker RH
    Am J Psychiatry; 1999 May; 156(5):796-7. PubMed ID: 10327920
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholinergic-dopaminergic imbalance in Pisa syndrome.
    Villarejo A; Camacho A; García-Ramos R; Moreno T; Penas M; Juntas R; Ruiz J
    Clin Neuropharmacol; 2003; 26(3):119-21. PubMed ID: 12782913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil in schizophrenia--is it helpful? An experimental design case study.
    MacEwan GW; Ehmann TS; Khanbhai I; Wrixon C
    Acta Psychiatr Scand; 2001 Dec; 104(6):469-72. PubMed ID: 11782241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil for the treatment of psychosis in dementia with Lewy bodies.
    Fergusson E; Howard R
    Int J Geriatr Psychiatry; 2000 Mar; 15(3):280-1. PubMed ID: 10713588
    [No Abstract]   [Full Text] [Related]  

  • 10. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
    Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
    Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can donepezil be considered a mild antipsychotic in dementia treatment? A report of donepezil use in 6 patients.
    Terao T; Shimomura T; Nakamura J
    J Clin Psychiatry; 2003 Nov; 64(11):1392-3. PubMed ID: 14658957
    [No Abstract]   [Full Text] [Related]  

  • 13. Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
    Pérez M; Tůma I; Pytela O; Kadlecová E; Zemanová M; Lenderová Z
    Eur Psychiatry; 2006 Dec; 21(8):548-50. PubMed ID: 16797936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive dyskinesia rates with atypical antipsychotics in older adults.
    Jeste DV
    J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
    Formiga F; Fort I; Pérez-Castejón JM; Ruiz D; Duaso E; Riu S
    Rev Clin Esp; 2006 Sep; 206(8):411-2; author reply 412-3. PubMed ID: 16863635
    [No Abstract]   [Full Text] [Related]  

  • 18. Donepezil for Down's syndrome.
    Kishnani PS; Spiridigliozzi GA; Heller JH; Sullivan JA; Doraiswamy PM; Krishnan KR
    Am J Psychiatry; 2001 Jan; 158(1):143. PubMed ID: 11136652
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical forms of severe tardive dyskinesia.
    Gardos G; Cole JO; Salomon M; Schniebolk S
    Am J Psychiatry; 1987 Jul; 144(7):895-902. PubMed ID: 2886062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.